Literature DB >> 24593801

Burden of schizophrenia on selected comorbidity costs.

Marie-Hélène Lafeuille1, Jason Dean, John Fastenau, Jessica Panish, William Olson, Michael Markowitz, Mei Sheng Duh, Patrick Lefebvre.   

Abstract

Patients suffering from schizophrenia tend to have high rates of medical comorbidities and mortality.This study evaluated the healthcare costs of patients with schizophrenia and specific comorbidities relative to patients without schizophrenia with the same comorbidities, using Medicaid insurance claims databases from five states (from 2001-2010). The most common comorbidities were hypertension (48.8%), substance abuse (39.1%) and diabetes (28.4%). Patients with schizophrenia incurred greater all-cause monthly healthcare costs (cost difference [95% CI]: US$978 [933; 1024]) and comorbidity-related costs (cost difference [95% CI]: US$288 [269; 307]). Schizophrenia was also associated with significantly higher comorbidity-related costs in each comorbidity subgroup (among the three most common comorbidities: 99% higher in hypertension, 293% in substance abuse, and 105% in diabetes). The results suggest that patients with schizophrenia and comorbidities common in patients with schizophrenia had higher all-cause and comorbidity-related healthcare costs compared with patients without schizophrenia with the same comorbidities.

Entities:  

Mesh:

Year:  2014        PMID: 24593801     DOI: 10.1586/14737167.2014.894463

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  5 in total

1.  Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.

Authors:  Marie-Hélène Lafeuille; Christian Frois; Michel Cloutier; Mei Sheng Duh; Patrick Lefebvre; Jacqueline Pesa; Zoe Clancy; John Fastenau; Mike Durkin
Journal:  Am Health Drug Benefits       Date:  2016-10

2.  Severe mental illness and health service utilisation for nonpsychiatric medical disorders: A systematic review and meta-analysis.

Authors:  Amy Ronaldson; Lotte Elton; Simone Jayakumar; Anna Jieman; Kristoffer Halvorsrud; Kamaldeep Bhui
Journal:  PLoS Med       Date:  2020-09-14       Impact factor: 11.069

3.  Unmet Opportunity: Intensive Care Transition Intervention for Individuals With Serious Medical-Psychiatric Illnesses.

Authors:  Thomas E Smith; Leslie A Marino; Mark Olfson
Journal:  Psychiatr Serv       Date:  2021-04-23       Impact factor: 4.157

4.  Predicting Future High-Cost Schizophrenia Patients Using High-Dimensional Administrative Data.

Authors:  Yajuan Wang; Vijay Iyengar; Jianying Hu; David Kho; Erin Falconer; John P Docherty; Gigi Y Yuen
Journal:  Front Psychiatry       Date:  2017-06-30       Impact factor: 4.157

5.  Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.

Authors:  Dominic Pilon; Erik Muser; Patrick Lefebvre; Rhiannon Kamstra; Bruno Emond; Kruti Joshi
Journal:  BMC Psychiatry       Date:  2017-06-02       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.